International journal of gynaecology and obstetrics : the official organ of the International Federation of Gynaecology and Obstetrics
-
Int J Gynaecol Obstet · Jun 2000
Comparative Study Clinical Trial Controlled Clinical TrialLow-molecular-weight heparin for thrombophilia in pregnant women.
Low-molecular-weight heparin (LMWH) is the anticoagulant of choice during pregnancy because it is associated with a low incidence of osteoporosis and thrombocytopenia. Antithrombotic therapy has recently been used to prevent pregnancy loss in high-risk patients with evidence of acquired or congenital thrombophilia. The aim of the present study was to gain further information on the teratogenic potential of LMWH in this patient group. ⋯ Despite the small size of the study groups, our results support the assumption that the use of LMWH is safe, at least as a teratogenic agent, in patients with thrombophilia throughout pregnancy.